Show simple item record

dc.contributor.authorPlummer, R
dc.contributor.authorLorigan, Paul C
dc.contributor.authorSteven, N
dc.contributor.authorScott, L
dc.contributor.authorMiddleton, M
dc.contributor.authorWilson, R
dc.contributor.authorMulligan, E
dc.contributor.authorCurtin, N
dc.contributor.authorWang, D
dc.contributor.authorDewji, R
dc.contributor.authorAbbattista, A
dc.contributor.authorGallo, J
dc.contributor.authorCalvert, H
dc.date.accessioned2013-07-08T15:02:57Z
dc.date.available2013-07-08T15:02:57Z
dc.date.issued2013-05
dc.identifier.citationA phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. 2013, 71 (5):1191-9 Cancer Chemother Pharmacolen_GB
dc.identifier.issn1432-0843
dc.identifier.pmid23423489
dc.identifier.doi10.1007/s00280-013-2113-1
dc.identifier.urihttp://hdl.handle.net/10541/295488
dc.description.abstractpoly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer chemotherapy and pharmacologyen_GB
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDacarbazine
dc.subject.meshDisease-Free Survival
dc.subject.meshDrug Synergism
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIndoles
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshPoly(ADP-ribose) Polymerases
dc.subject.meshSkin Neoplasms
dc.subject.meshSurvival Rate
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleA phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.en
dc.typeArticleen
dc.contributor.departmentInstitute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. ruth.plummer@ncl.ac.uken_GB
dc.identifier.journalCancer Chemotherapy and Pharmacologyen_GB
html.description.abstractpoly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma.


This item appears in the following Collection(s)

Show simple item record